Moreover, the suppression of CBP switches the balance to β-catenin/p300 mediated cell differentiation, suggesting an entirely novel approach for the treatment of CML, with the therapeutic potential to treat BCR-ABL-T315I mutant CML. This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.